Walgreen Co.'s (WAG) fiscal fourth-quarter earnings jumped 86% as pharmacy section's sales continued to improve and as an accounting provision and higher acquisition-related costs weighed on its year-earlier results.
The company's margins also improved slightly in the latest period. Drugstore retailers like Walgreen have posted higher gross margins of late, aided by a wave of generic-drug offerings that carry higher profitability than nongenerics. However, generic drugs also command lower prices.
The shift in consumers' drug purchases toward generics has led pharmacy companies to take steps to improve their performance--including a recent alliance by Walgreen and European drug giant Alliance Boots GmbH with drug wholesaler AmerisourceBergen Corp. (ABC).
Chief Executive Greg Wasson said the company saw improvement in its daily-living business, resulting from investments and enhanced execution. Meanwhile, the company's pharmacy business also continued to strengthen and the company increased its retail-pharmacy market share for the year to 19.1%, he added.
For the quarter ended Aug. 31, Walgreen reported a profit of $657 million, or 69 cents a share, up from $353 million, or 39 cents a share, a year earlier. The latest period included income of one cent related to the last-in-first-out accounting method, while the year-before period included a LIFO provision of 10 cents a share. Excluding the LIFO impacts, acquisition-related expenses and amortization, costs related to its Alliance Boots deal and other special items, per-share earnings rose to 73 cents from 63 cents.
Revenue rose 5.1% to $17.94 billion. Total same-store sales were up 4.6% as same-store sales increased 1.6% in the front of the store and were up 6.4% in the pharmacy section.
Analysts polled by Thomson Reuters most recently projected earnings of 72 cents on revenue of $17.95 billion.
Gross margin widened slightly to 28.9% from 28.3%.
Same-store customer traffic slipped 1.9% while basket size improved 3.6%.
Shares were up 50 cents to $54.30 premarket. The stock is up 45% since the start of the year.
Write to Nathalie Tadena at firstname.lastname@example.org
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
(END) Dow Jones Newswires
October 01, 2013 08:35 ET (12:35 GMT)Copyright (c) 2013 Dow Jones & Company, Inc.
|Walgreen Fourth-Quarter Profit Up 86% as Pharmacy Sales Improve ()|
|Walgreens to Help Provide Up to 3 Million Life-Saving Vaccines for Children who Need Them Most Through Donation to United Nations Foundation's Shot@Life Campaign ()|
|General Electric 3rd-Quarter Profit Down 8.6% on Charges, Weak Financial Revenue (2013/10/18)|
|CME Group 3rd-Quarter Net Up 8.6% on Stronger Trading Volume ()|
|Siemens to Buy Back Shares, 4Q Profit Declines Slightly (2013/11/7)|
|Whole Foods 4th-Quarter Profit Up 7.1%; Fiscal Year Outlook Cut (2013/11/6)|
|Liberty Interactive Operating Profit Up 3.1% ()|
|Sharps Compliance Reports Fourth Quarter Fiscal 2013 Revenue up 16%, Finishes Year With $21.5 Million in Revenue (2013/8/14)|
|Kinder Morgan Third-Quarter Profit Up 43%; Kinder Morgan Energy Earnings Up 70% (2013/10/16)|
|UPDATE: St. Jude Medical 3rd-Quarter Profit Up 49% Amid Stabilization of Key Product Line ()|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.